• Dignitana AB
    Traktorgränden 3, SE - 226 60 Lund, Sweden
    +46 46 163090
  • Quotes

    DigniCap Delta changes everything about the way scalp cooling is done today. Australia is a very important market for us and, as scalp cooling has become a standard of care for patients here, the Delta device will enable our partner sites to offer this valuable therapy option to more patients and much more efficiently.
    William Cronin, CEO of Dignitana
    Clinicians want to help patients maintain a level of privacy and control that is often lost after diagnosis. Helping cancer care teams address quality of life is an essential component of what we do every single day. Our DigniCap Dignitaries are just one more way we provide patients with a highly personalized level of support and care.
    William Cronin, CEO Dignitana AB
    Identity, privacy and confidence became important and very personal concerns when I was diagnosed with cancer and put on a chemotherapy regimen. I’m incredibly honored by this opportunity to help others who I’m sure will have tons of questions, just as I did. To have someone who can help you know what to expect is so important. I can’t wait to connect with other cancer patients looking to keep their hair during chemo.
    Sharon Yapoujian, DigniCap Dignitary
    The technological advances engineered into the new DigniCap Delta bring scalp cooling therapy to a whole new level, This streamlined model offers a new gold standard in patient comfort, flexibility and precision fit and is designed for ease of use and efficiency by clinicians.
    William Cronin, CEO Dignitana AB
    As the leading innovator in scalp cooling technology we know first-hand the importance of knowledge, early diagnoses and treatment. We welcome initiatives that highlight the quest for supportive cancer care and enhance quality of life options.
    William Cronin, CEO Dignitana AB
    We are pleased that this approval comes at a time when both awareness of and demand for scalp cooling are rapidly increasing. The clearance of Delta now provides a clear pathway for growth in the important U.S. market and beyond. It is the biggest step yet in the evolution of Dignitana and is the result of a tremendous effort from our staff, partner sites, regulatory team and contract manufacturer.
    William Cronin
    DigniCap Delta changes everything about the way scalp cooling is done today. In the value-based U.S. health care system providers tell us they want to improve the clinical process, reduce nursing intervention and optimize patient outcomes. This new device, developed along with our partner sites, allows them to accomplish all three of these objectives. We are thrilled to offer patients and clinicians this state-of-the-art advancement in cancer care.
    William Cronin
    Dignitana is moving forward with positive momentum. We are confident that the new system will provide clear benefits to hospitals and patients and we look forward to accelerated growth with the launch of this new system in the first half of 2019.
    William Cronin, Chief Executive Officer
    This is a very important first step in our commitment to bring DigniCap to the Asian market in conjunction with our distribution partner Konica Minolta. As of yet there is no data from a clinical study of scalp cooling with an exclusively Asian population. Beijing Cancer Hospital is a leading cancer treatment facility in Asia and we are eager to work with them in this milestone study.
    William Cronin, CEO Dignitana AB
    The results we posted this quarter represent a very important milestone for Dignitana. Quarterly revenue for the company reached 9,022 TSEK. With the organizational restructuring we have implemented, the company is close to reaching a breakeven point in regard to our costs for continuing operations.
    - William Cronin, CEO, Dignitana AB
    As Dignitana now moves into a new chapter, the broad and varied expertise of the proposed slate of Thomas Kelly, Ingrid Atteryd Heiman and Mikael Wahlgren will be a tremendous asset to our continued growth and development.
    William Cronin, CEO Dignitana AB
    We hope this expanded FDA clearance will be welcome news for thousands of Americans diagnosed with solid tumors each year.
    Bill Cronin, CEO Dignitana Inc
    The new decision by the FDA means that our potential market in the US is more than tripled.
    Johan Ericsson
    “The CHILL Registry is an incredible platform that will allow us to track progress and connect with physicians around the world to ensure that we can continue to deliver the most effective scalp cooling treatments available.”
    Johan Ericsson, CEO Dignitana AB
    “Dignitana is keen to align with support groups in the area to facilitate awareness and access to DigniCap treatments”
    William Cronin, Chief Executive Officer of Dignitana, Inc
    Mario Lacouture, MD, Director of the Oncodermatology Program at Memorial Sloan Kettering
    Scalp cooling is clinically proven and can be an important tool for many women in treatment for breast cancer.
    Mario Lacouture, MD, Director of the Oncodermatology Program at Memorial Sloan Kettering
    As a world leader in comprehensive cancer care, we are proud to be able to offer our patients across the New York metro area this new FDA-cleared advancement that addresses one of the most distressing and most visible side effects of chemotherapy.
    William Cronin, Chief Executive Officer of Dignitana, Inc.
    We have just passed the one-year anniversary of clearance by the FDA for DigniCap® in the U.S., and we are proud to add Memorial Sloan Kettering, one of the top comprehensive cancer centers in the U.S., to the growing number of facilities that are providing this treatment option to patients on a large scale.
    William Cronin, Chief Executive Officer of Dignitana, Inc.
    Bringing the DigniCap® system to MSK is an important milestone for Dignitana.
    We are pleased with the consistent strong growth we are experiencing in the U.S. since FDA clearance nine months ago. The DigniCap system is being included as an integral part of the treatments offered by national leaders in comprehensive breast health services in the U.S. Up to date, forty-seven DigniCap scalp-cooling systems have been ordered for installation by US customers.
    Jan Richardsson, Chief Executive Officer of Dignitana
    We are very excited that DigniCap® is being so well-received in the U.S., and that we’ve been able to quickly and effectively fulfil product requests. From the New York Metropolitan area to communities throughout the midwest, the south, and California, it is clear that DigniCap is filling an important need in quality of life cancer care and medical centers are eagerly promoting its addition to their cancer services.
    Jan Richardsson, Chief Executive Officer of Dignitana
    This FDA clearance means that finally, breast cancer patients in the U.S. will have access to a convenient, safe and scientifically proven option for reducing chemotherapy-induced hair loss.
    Jan Richardsson, CEO Dignitana AB
    Working with the professionals at our clinical trial sites has given us a significant head start in learning how best to provide the DigniCap® scalp cooling system here in the U.S.
    Bill Cronin, COO Dignitana Inc.
    The time is right to introduce DigniCap® at SABCS to physicians who are eager to provide their patients with an alternative to one of the most widely feared side effects of chemotherapy.
    Jan Richardsson, CEO Dignitana AB
    “We feel honored to be nominated and ranked as one of the fastest growing technology companies by Deloitte. We’ve grown during the ranking’s period, and we have fantastic journey in front of us with United States Food and Drug Administration approval pending.”
    Jan Richardsson, CEO, Dignitana AB
    To have recruited all patients is a milestone for our company and a major step forward in our PMA process.
    Erika Bågeman, Clinical Affairs Manager, Dignitana AB